| Literature DB >> 26716838 |
Dana A M Mustafa1, Anieta M Sieuwerts2, Marcel Smid2, Vania de Weerd2, Marcel van der Weiden1, Marion E Meijer-van Gelder2, John W M Martens2, John A Foekens2, Johan M Kros1.
Abstract
BACKGROUND: Gene expression profiling of tumors is a successful tool for the discovery of new cancer biomarkers and potential targets for the development of new therapeutic strategies. Reliable profiling is preferably performed on fresh frozen (FF) tissues in which the quality of nucleic acids is better preserved than in formalin-fixed paraffin-embedded (FFPE) material. However, since snap-freezing of biopsy materials is often not part of daily routine in pathology laboratories, one may have to rely on archival FFPE material. Procedures to retrieve the RNAs from FFPE materials have been developed and therefore, datasets obtained from FFPE and FF materials need to be made compatible to ensure reliable comparisons are possible. AIM: To develop an efficient method to compare gene expression profiles obtained from FFPE and FF samples using the same platform.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26716838 PMCID: PMC4696787 DOI: 10.1371/journal.pone.0144097
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
List of FFPE-FF sample pairs included in the analysis.
| Number of pairs | Tumor types | Number of hybridizations of FFPE | Number of hybridizations of FF |
|---|---|---|---|
| 10 | breast cancer | 3 samples 2x 7 samples 1x | 3 samples 2x 7 samples 1x |
| 4 | brain metastases of lung cancer | 2 samples 2x 2 samples 1x | 2 samples 2x 2 samples 1x |
| 3 | brain metastases of kidney cancer | 1x | 1x |
| 2 | brain metastases of colon cancer | 1x | 1x |
| 1 | brain metastases of prostate cancer | 1x | 1x |
| 1 | brain metastasis of esophageal cancer | 1x | 1x |
| 1 | brain metastasis of leiomyosarcoma | 1x | 1x |
| 1 | brain metastasis of ovarian cancer | 1x | 1x |
| 1 | brain metastasis of endometrium | 1x | 1x |
| 1 | Brain metastasis of melanoma | 1x | 1x |
| 1 | brain metastasis of ACUP | 1x | 1x |
| 2 | breast cancer cell lines | 2 x | 2 x |
FFPE = formalin-fixed, paraffin-embedded; FF = fresh frozen; ACUP = adenocarcinoma of unknown primary.
Fig 1Flow chart of the method followed to analyze FFPE-FF sample pairs.
70 FFPE and FF measurements (28 FFPE-FF pairs + 14 duplicate hybridizations) were used to establish a sample-quality threshold. A threshold of 2,208 was chosen and 7 FFPE samples (6x of the duplicates and 1x of the single hybridizations) with a median below this threshold were considered of poor quality and were excluded. Because the analysis is based on FFPE-FF pairs, 7 FF pairs matching the 7 FFPE samples with low median of the reference genes were excluded from the analysis. In addition, to exclude bias in the unsupervised analysis to be performed later, the two samples that remained from the duplicate hybridizations were excluded from the analysis. The duplicate samples were selected based on their median reference gene values; duplicate samples with the lowest median reference gene values were excluded from the analysis. Due to the duplicate hybridizations which did pass the exclusion criteria, only 1 sample pair was lost to the analysis because there was no FFPE data available. The other 25 tumors and 2 cell lines had all FFPE and FF data available for further analyses In total, 54 FFPE-FF measurements (27 FFPE-FF sample pairs) were used to develop the ruler based on the reliably measured probes.
Stable reference gene selection based on 28 FF-FFPE pairs (56 samples).
| Gene name | Illumina code | Average probe intensity | GeNorm | NormFinder | Intragroup | Intergroup | |||
|---|---|---|---|---|---|---|---|---|---|
| M-Value | SD | Accumulated SD | FF | FFPE | FF | FFPE | |||
|
| ILMN_1343291 | 7733 | 0.35 | 0.32 | 0.20 | 0.10 | 0.12 | -0.08 | 0.08 |
|
| ILMN_2038778 | 9027 | 0.41 | 0.53 | 0.13 | 0.09 | 0.26 | -0.32 | 0.32 |
|
| ILMN_2094718 | 3452 | 0.53 | 0.52 | 0.13 | 0.27 | 0.29 | -0.06 | 0.06 |
|
| ILMN_203877 | 19568 | 0.23 | 0.37 | 0.15 | 0.10 | 0.19 | 0.00 | 0.00 |
|
| ILMN_1713369 | 9813 | 0.47 | 0.41 | 0.14 | 0.05 | 0.26 | 0.15 | -0.15 |
|
| ILMN_1693311 | 5024 | 0.50 | 0.42 | 0.13 | 0.08 | 0.29 | 0.00 | 0.00 |
|
| ILMN_2331501 | 3189 | 0.60 | 0.59 | 0.13 | 0.11 | 0.44 | 0.28 | -0.28 |
|
| ILMN_2191428 | 1766 | 0.57 | 0.57 | 0.13 | 0.16 | 0.37 | 0.25 | -0.25 |
|
| ILMN_1772132 | 21641 | 0.23 | 0.25 | 0.25 | 0.05 | 0.09 | -0.06 | 0.06 |
|
| ILMN_1726306 | 6839 | 0.44 | 0.35 | 0.16 | 0.08 | 0.19 | -0.04 | 0.04 |
|
| ILMN_2148459 | 10474 | 0.29 | 0.33 | 0.17 | 0.05 | 0.15 | -0.14 | 0.14 |
|
|
|
|
|
|
|
|
|
| |
|
| ILMN_2216852 | 22697 | 0.84 | 1.10 | 0.14 | 0.54 | 0.63 | -0.76 | 0.76 |
|
| ILMN_1722634 | 16970 | 0.80 | 0.88 | 0.13 | 0.09 | 0.57 | -0.65 | 0.65 |
|
| ILMN_1681374 | 3647 | 0.69 | 0.64 | 0.13 | 0.23 | 0.58 | 0.13 | -0.13 |
|
| ILMN_1801928 | 5516 | 0.98 | 1.54 | 0.16 | 1.80 | 2.24 | 0.61 | -0.61 |
|
| ILMN_2051232 | 6690 | 0.92 | 1.39 | 0.15 | 1.02 | 0.46 | -1.04 | 1.04 |
|
| ILMN_1669878 | 3186 | 0.73 | 0.79 | 0.13 | 0.08 | 0.84 | 0.41 | -0.41 |
|
| ILMN_2385647 | 9113 | 0.67 | 0.73 | 0.13 | 0.10 | 0.79 | 0.31 | -0.31 |
|
| ILMN_1673711 | 23216 | 0.78 | 0.83 | 0.13 | 0.08 | 0.59 | -0.58 | 0.58 |
|
| ILMN_2347949 | 2145 | 0.71 | 0.68 | 0.13 | 0.20 | 0.64 | -0.23 | 0.23 |
|
| ILMN_2056975 | 5360 | 0.75 | 0.83 | 0.13 | 0.09 | 0.56 | 0.58 | -0.58 |
|
| ILMN_1783424 | 3830 | 0.87 | 1.15 | 0.14 | 0.19 | 1.68 | 0.61 | -0.61 |
|
| ILMN_2157277 | 11760 | 0.65 | 0.64 | 0.13 | 0.16 | 0.59 | 0.22 | -0.22 |
|
| ILMN_2232177 | 9990 | 0.62 | 0.62 | 0.13 | 0.06 | 0.38 | 0.40 | -0.40 |
All samples from Table 1 were used. In case of duplicate hybridizations, the sample with the highest median value for the reference genes was selected. GeNorm and NormFinder software were used to calculate the stability of genes. M-value; the average expression stability value, for which an arbitrarily cut-off at 0.6 was used to assign genes as stably expressed or not. ACTB = Actin-Beta; ATP5B = ATP Synthase Subunit Beta; B2M = beta-2-microglobin; EEF1A1 = eukaryotic translation elongation factor 1 alpha 1; GAPDH = Glyceraldehyde-3-Phosphate Dehydrogenase; HMBS = hydroxymethylbilane synthase; HPRT1 = hypoxanthine phosphoribosyltransferase 1; RPL13A = ribosomal protein L13a; TPT1 = tumor protein, translationally-controlled 1; UBB = ubiquitin B; UBC = ubiquitin C; ACTN1 = actinin, alpha 1; AKR1D1 = aldo-keto reductase family 1, member D1; ALAS1 = aminolevulinate, delta-, synthase 1; ALDOA = aldolase A, fructose-bisphosphate; G6PD = glucose-6-phosphate dehydrogenase; GUSB = glucuronidase, beta; HSP90AB1 = heat shock protein 90kDa alpha (cytosolic), class B member 1; NUCB1 = nucleobindin 1; PGK1 = phosphoglycerate kinase 1; PUM1 = pumilio RNA-binding family member 1; SDHA = succinate dehydrogenase complex, subunit A, flavoprotein (Fp); TMBIM6 = transmembrane BAX inhibitor motif containing 6; YWHAZ = tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta.
* Belong to the housekeeping gene set of Illumina.
Correlation between FFPE-FF sample pairs.
| Number of Probes | |||||
|---|---|---|---|---|---|
| Sample pairs | 1,432 | 2,530 | 3,351 | 24,526 | |
| 1 | Breast Ca. 1 | 0.78 | 0.70 | 0.66 | 0.57 |
| 2 | Breast Ca. 2 | 0.88 | 0.84 | 0.83 | 0.81 |
| 3 | Breast Ca. 3 | 0.94 | 0.93 | 0.92 | 0.90 |
| 4 | Breast Ca. 4 | 0.87 | 0.83 | 0.81 | 0.76 |
| 5 | Breast Ca. 5 | 0.92 | 0.88 | 0.87 | 0.82 |
| 6 | Breast Ca. 6 | 0.86 | 0.82 | 0.81 | 0.76 |
| 7 | Breast Ca. 7 | 0.90 | 0.86 | 0.85 | 0.81 |
| 8 | Breast Ca. 8 | 0.81 | 0.80 | 0.80 | 0.90 |
| 9 | Breast Ca. 9 | 0.99 | 0.99 | 0.99 | 0.99 |
| 10 | Breast Ca. 10 | 0.84 | 0.80 | 0.78 | 0.79 |
| 11 | Brain meta. lung Ca. 1 | 0.86 | 0.83 | 0.81 | 0.76 |
| 12 | Brain meta. Lung Ca. 2 | 0.85 | 0.80 | 0.78 | 0.75 |
| 13 | Brain meta. Lung Ca. 3 | 0.76 | 0.72 | 0.72 | 0.74 |
| 14 | Brain meta. Lung Ca. 4 | 0.86 | 0.84 | 0.83 | 0.81 |
| 15 | Brain meta. colon Ca. 1 | 0.90 | 0.87 | 0.86 | 0.82 |
| 16 | Brain meta. colon Ca. 2 | 0.79 | 0.73 | 0.70 | 0.55 |
| 17 | Brain meta. kidney Ca. 1 | 0.88 | 0.84 | 0.83 | 0.74 |
| 18 | Brain meta. kidney Ca. 2 | 0.83 | 0.78 | 0.77 | 0.67 |
| 19 | Brain meta. kidney Ca. 3 | 0.90 | 0.86 | 0.85 | 0.77 |
| 20 | Brain meta. prostate Ca. | 0.87 | 0.85 | 0.83 | 0.73 |
| 21 | Brain meta. oesophagus Ca. | 0.84 | 0.79 | 0.78 | 0.69 |
| 22 | Brain meta. Leiomyosarcoma | 0.74 | 0.66 | 0.63 | 0.55 |
| 23 | Brain meta. ovarian Ca. | 0.83 | 0.80 | 0.78 | 0.75 |
| 24 | Brain meta. endometrium Ca. | 0.87 | 0.83 | 0.81 | 0.76 |
| 25 | Brain meta. ACUP | 0.83 | 0.79 | 0.78 | 0.75 |
| 26 | Breast cell-line [MDA-MB-231] | 0.96 | 0.96 | 0.96 | 0.93 |
| 27 | Breast cell-line [SKBR3] | 0.95 | 0.94 | 0.94 | 0.90 |
|
| 25/27 | 21/27 | 19/27 | 1/27 | |
Rows 1 through 27 represent the paired samples of which the FFPE and FF parts were separately run on the Illumina WG-DASL V3 platform. The right four columns show the Spearman rank correlation coefficients between the expression values of the FF and FFPE materials for the distinct P-values (0.01; 0.05; 0.10 and N.A. = Not Applicable). The upper row shows the numbers of probes included for the distinct levels of significance. The number of matched pairs following unsupervised hierarchical clustering is shown in the bottom row.
Fig 2Dendrograms of matched FF and FFPE pairs at the three cut-off values.
(A) Clusters based on 1,432 probes (P<0.01): only 2 FFPE samples did not cluster with their FF counter pairs. (B) Clusters based on 2,530 probes (P<0.05): 6 FFPE samples did not cluster with their FF counter pairs. (C) Clusters based on 3,351 probes (P<0.1): 8 FFPE samples did not cluster with their FF counter pair sample. (D) Clusters based on all the 24,526 profiled probes: the main two arms of the dendrogram are based on the FFPE or FF samples. Each square represents a sample; Blue: FFPE; Green: FF, Red asterix indicates the FFPE samples that did not cluster with their FF counterpart.
Fig 3Ruler of the three cut-off values used to compare the gene expression profiles of FFPE and FF samples.
Each Pearson P-value results in different numbers of probes to be included for further analysis.